Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil can cause under-eye bags due to fluid retention, and some users find relief by stopping its use or switching to oral forms. Collagen supplements, reducing sodium intake, and using skincare products like eye creams and sunscreen may help improve the appearance of eye bags.

Topical antihistamine creams, like diphenhydramine, are being considered for scalp inflammation and itchiness as an adjunct to standard hair loss treatments like minoxidil and finasteride. The user is cautious about oral antihistamines due to potential side effects and is exploring topical options.

A 26-year-old has been using oral 0.5 mg dutasteride and 3 mg minoxidil for 6 months to treat stress-induced hair loss, noticing progress without side effects. They plan to continue the treatment for 1-1.5 years before considering a hair transplant and switching to mesotherapy.

The conversation discusses switching from topical to oral minoxidil while using oral finasteride, with concerns about hair shedding and side effects like puffy eyes. Users suggest gradually transitioning by using both forms of minoxidil initially, then reducing topical use.

After switching from finasteride to 0.5 mg dutasteride daily, the user experienced thinner hair but no shedding. They are considering continuing dutasteride and possibly using oral minoxidil, while also dealing with allergy-like symptoms possibly unrelated to the medication.

Alcohol-free minoxidil options in Europe, particularly from a German pharmacy, are recommended for those with seborrheic dermatitis. Users suggest alternatives like Alopexy and Doppelherz foam, and emphasize avoiding propylene glycol and alcohol to reduce irritation.

A 24-year-old reported new hair growth on temples after 3.5 months of using topical minoxidil without shedding. They plan to add finasteride to maintain progress, as minoxidil alone may not be enough long-term.

A 19-year-old shares his hair loss experience and treatment routine, which includes 1mg finasteride daily, 2mg oral minoxidil daily, ketoconazole shampoo every 2 days, and a healthy lifestyle. He notes that oral minoxidil is showing better results than topical minoxidil.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Amplifica raised $26 million to advance its injectable treatments for hair growth. The funding will support the clinical development of their novel therapies.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.